GlassScriptPhysician profile
Awais Khan
NPI 1720233018
$2,224.56
in general payments reported to CMS, 2019-2025
37 companies · $20.66 in 2025
The $20.66 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $761 · 2021: $63.32 · 2022: $12.35 · 2023: $106 · 2025: $20.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $127.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $232.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $206.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $180.27 | 2019-2020 | |
| Genzyme Corporation | $149.70 | 2019-2020 | |
| Foundation Medicine, INC. | $130.33 | 2019-2020 | |
| Pfizer INC. | $110.70 | 2019-2020 | |
| Amgen INC. | $89.32 | 2019-2020 | |
| Janssen Biotech, INC. | $88.95 | 2019-2020 | |
| Celgene Corporation | $80.20 | 2019-2023 | Reblozyl |
| Lilly USA, LLC | $78.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.96 | 2019-2020 | |
| Emd Serono, INC. | $72.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.15 | 2020-2025 | Ojjaara |
| Dova Pharmaceuticals | $59.72 | 2019-2020 | |
| Seagen INC. | $53.96 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $49.58 | 2019-2023 | Padcev |
| Array Biopharma INC | $49.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $47.71 | 2019-2020 | |
| Genentech USA, INC. | $40.06 | 2019-2021 | |
| Eisai INC. | $36.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.33 | 2020 | |
| Incyte Corporation | $28.77 | 2019-2020 | |
| Tesaro, INC. | $26.03 | 2019 | |
| Exelixis INC. | $24.20 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $23.07 | 2023 | Bracanalysis Cdx |
| Teva Pharmaceuticals USA, INC. | $22.05 | 2019-2020 | |
| Abbvie INC. | $17.96 | 2020 | |
| Aurobindo Pharma USA, INC. | $17.73 | 2019 | |
| Eusa Pharma (US) LLC | $16.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.27 | 2020 | |
| Sirtex Medical INC | $13.59 | 2020 | |
| Clovis Oncology, INC. | $12.96 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.88 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.35 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Veracyte, INC. | $1.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Awais Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.